(Sharecast News) – Addiction treatment drug maker Indivior said it has agreed to pay $385m to resolve the final lawsuit claims against it in the long-running Suboxone anti-trust case.
The company, which makes anti-opioid treatments, said it would also take a $228m charge in the third quarter, which will be excluded from adjusted earnings.
“This charge represents the additional amount above the current remaining provision of $157m for the antitrust multi-district litigation, which reflects the previously announced settlement agreements with the States and End Payors,” Indivior said on Monday.
A trial that was scheduled to start on October 30 has been cancelled, it added.
“We are pleased to achieve this settlement to conclude this legacy multi-district antitrust matter,” said Indivior chief executive Mark Crossley.
“The resolution of this litigation, which was filed over a decade ago, provides greater certainty for all Indivior stakeholders and allows us to continue focusing on our important work for patients suffering from opioid use disorder and mental health illnesses around the world.”
Reporting by Frank Prenesti for Sharecast.com
